88 related articles for article (PubMed ID: 7873228)
1. [Experimental study of the utilization of combined interferon chemotherapy in the treatment of laryngeal cancer].
Bergler W; Bujía J
Acta Otorrinolaringol Esp; 1994; 45(6):407-10. PubMed ID: 7873228
[TBL] [Abstract][Full Text] [Related]
2. [Current approaches to combined treatment of recurrent respiratory papillomatosis].
Pluzhnikov MS; Riabova MA; Karpishchenko SA; Katinas EB
Vestn Otorinolaringol; 2008; (4):29-37. PubMed ID: 18837150
[No Abstract] [Full Text] [Related]
3. [A study of neoadjuvant chemotherapy in the treatment of cancer of pyriform sinuses].
Ramos Fernández J; Avilés Mañoso P; Martín Atienza R; Lozano Barriuso MA; Fernández-Vega M
Acta Otorrinolaringol Esp; 1994; 45(6):451-6. PubMed ID: 7873237
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
[TBL] [Abstract][Full Text] [Related]
5. [Pediatric laryngeal papillomatosis: our experience (three cases)].
Rodrigo Chiner O; Gisbert Aguilar J; Sánchez Alcón MD; Morera Pérez C
Acta Otorrinolaringol Esp; 1995; 46(5):365-6. PubMed ID: 8554807
[TBL] [Abstract][Full Text] [Related]
6. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells.
Damdinsuren B; Nagano H; Wada H; Kondo M; Ota H; Nakamura M; Noda T; Natsag J; Yamamoto H; Doki Y; Umeshita K; Dono K; Nakamori S; Sakon M; Monden M
Int J Oncol; 2007 Jan; 30(1):201-8. PubMed ID: 17143530
[TBL] [Abstract][Full Text] [Related]
7. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
8. Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study.
Recchia F; Rea S; Pompili P; Casucci D; Rea MJ; Rizzo F; Gulino A; Frati L
Clin Ter; 1995 Oct; 146(10):603-10. PubMed ID: 8585877
[TBL] [Abstract][Full Text] [Related]
9. Larynx preservation: what is the standard treatment?
Horn S; Ozsahin M; Lefèbvre JL; Horiot JC; Lartigau E;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e97-e105. PubMed ID: 21185198
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effects of interferon: a personal history.
Gresser I
Biochimie; 2007; 89(6-7):723-8. PubMed ID: 17451861
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of juvenile papillomatosis of the larynx using interferon and levamisole].
Klacanský I; Jakubíková J; Borecký L; Fuchsberger N
Cesk Otolaryngol; 1986 Sep; 35(5):273-7. PubMed ID: 2428535
[No Abstract] [Full Text] [Related]
12. Organ preservation therapy for advanced-stage laryngeal carcinoma.
Hoffman HT; McCulloch T; Gustin D; Karnell LH
Otolaryngol Clin North Am; 1997 Feb; 30(1):113-30. PubMed ID: 8995140
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Barret JM; Kruczynski A; Etiévant C; Hill BT
Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
16. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
17. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells.
Obora A; Shiratori Y; Okuno M; Adachi S; Takano Y; Matsushima-Nishiwaki R; Yasuda I; Yamada Y; Akita K; Sano T; Shimada J; Kojima S; Okano Y; Friedman SL; Moriwaki H
Hepatology; 2002 Nov; 36(5):1115-24. PubMed ID: 12395321
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
20. Indole-3-carbinol enhances anti-proliferative, but not anti-invasive effects of oxaliplatin in colorectal cancer cell lines.
Howells LM; Neal CP; Brown MC; Berry DP; Manson MM
Biochem Pharmacol; 2008 May; 75(9):1774-82. PubMed ID: 18358454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
